Actively Recruiting
Evaluating Safety and Preliminary Effects of Single Subretinal JWK001 Injection Compared to Aflibercept in Neovascular Age-Related Macular Degeneration
Led by West China Hospital · Updated on 2026-08-20
50
Participants Needed
16
Research Sites
230 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and preliminary effectiveness of a single subretinal injection of JWK001 at different dose levels in people aged 50 to 85 with neovascular age-related macular degeneration nAMD. This Phase II, open-label, randomized study compares JWK001 with the standard treatment aflibercept. The goal is to understand how these treatments affect vision and eye health in patients needing anti-VEGF therapy for nAMD. Participants will be randomly assigned to receive either one subretinal injection of JWK001 at one of two doses 3 1010 or 6 1010 vector genomes in one study eye, or seven intravitreal injections of aflibercept 2 mg given at Weeks 2, 10, 18, 26, 34, 42, and 50 after starting the study. The study follows participants through these treatment schedules while monitoring response and safety. During the study, participants will have their vision tested using best-corrected visual acuity BCVA and other eye imaging assessments to measure central retinal thickness, macular neovascularization area, and leakage at multiple time points up to 5 years. Questionnaires on visual function and records of rescue treatments and safety events will also be collected. The main outcome is the change in BCVA from baseline at Week 34, with long-term follow-up extending through Year 5 to monitor ongoing effects and safety.
CONDITIONS
Brief Title
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
Research Team
L
Lu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here